New data show breakthrough microRNA-targeted therapy holds promise as new treatment for hepatitis C
A study published in Science reveals that SPC3649 successfully inhibits miR-122, a microRNA important for hepatitis C viral replication, significantly reducing the virus in the bloodstream and liver of chimpanzees chronically infected with HCV. The therapy's unique mechanism of action sets it apart from direct antiviral treatments.